Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
11 results
  • Melanoma, Lymphoma, Lung Cancer, Kidney Cancer, Bladder Cancer

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma

  • Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Thyroid Cancer, Breast Cancer, Head and Neck Cancer, Kidney Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Kidney Cancer

22-242          Phase III

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

  • Head and Neck Cancer, Breast Cancer, Melanoma, Lung Cancer, Kidney Cancer, Ovarian Cancer, Bladder Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Sarcoma, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Kidney Cancer, Gastric (Stomach) Cancer, Endometrial Cancer, Colorectal Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Kidney Cancer

20-741          Phase II

A PHASE 1B/2 , STUDY OF AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB-S6-500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA

  • Colorectal Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Rectal Cancer, Thymoma

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Tislelizumab in Patients with Select Advanced Cancers

  • Kidney Cancer

21-486          Phase I

A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2a stabilizing mutations

  • Head and Neck Cancer, Kidney Cancer, Esophageal Cancer, Lung Cancer

22-571          Phase I

A phase I/Ib, open-label, multi-center, study of QEQ278 in patients with advanced solid tumors

  • Kidney Cancer

20-236          Phase I

An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Showing 1 - 10 of 11 results